Effects of subsacute and chronic lead treatment on glucose homeostasis and renal cyclic AMP metabolism in rats.
The effects of chronic oral ingestion of lead in doses ranging from 20-80 ppm were compared with those seen after the subacute exposure of rats to a 10 mg/kg daily dose of the heavy metal for 7 days. Irrespective of the treatment regimen used, lead treatment significantly increased the activities of renal pyruvate carboxylase, phosphoenolpyruvate carboxykinase, fructose 1,6-diphosphatase and glucose 6-phosphatase. The observed enhancement of kidney gluconeogenic enzymes in chronically treated animals was associated with a stimulation of the adenylate cyclase-cyclic AMP system, a rise in blood blucose and urea as well as a depression in hepatic glycogen and serum immunoreactive insulin (IRI) levels. In contrast, subacute exposure to lead failed to significantly alter cyclic AMP metabolism and the concentrations of liver glycogen, blood glucose, serum urea or IRI. Whwereas the insulinogenic index (the ratio of serum IRI to blood glucose concentration) was markedly suppressed in chronically treated rats, this ratio remained within normal limits following subacute exposure to the heavy metal. However, a marked decrease in the insulinogenic index was observed in subacutely treated rats 15 min after the administration of a glucose load. The data provide evidence to show that increased glucose synthesis as well as suppressed pancreatic function may be responsible for lead-induced disturbances in glucose homeostasis.
D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D000242:Cyclic AMP / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006597:Fructose-Bisphosphatase / Q000378:metabolism; D005943:Gluconeogenesis / Q000187:drug effects*; D005952:Glucose-6-Phosphatase / Q000378:metabolism; D006706:Homeostasis / Q000187:drug effects; D007328:Insulin / Q000378:metabolism; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D007854:Lead / Q000008:administration & dosage / Q000633:toxicity*; D007855:Lead Poisoning / Q000378:metabolism*; D008297:Male; D010179:Pancreas / Q000187:drug effects; D010729:Phosphoenolpyruvate Carboxykinase (GTP) / Q000378:metabolism; D011766:Pyruvate Carboxylase / Q000378:metabolism; D051381:Rats
D007328:Insulin; D007854:Lead; D000242:Cyclic AMP; D006597:Fructose-Bisphosphatase; D005952:Glucose-6-Phosphatase; D010729:Phosphoenolpyruvate Carboxykinase (GTP); D000262:Adenylyl Cyclases; D011766:Pyruvate Carboxylase